Peter Thompson
Peter Thompson is the managing director of Barfoot & Thompson, Auckland's largest real estate agency, where he plays a crucial role in navigating the complexities of the real estate market. Under his leadership, the agency has seen significant sales increases and has managed a growing inventory of unsold homes, positioning him as a key figure in discussions about the recovery and performance of Auckland's housing market.
Global Media Ratings
Countries Mentioned
No country-level mention data available.
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
New Zealand:
Peter Thompson is mentioned as a guest at the philanthropic event.
6
New Zealand:
Peter Thompson is the managing director of Barfoot & Thompson and has been involved in various philanthropic efforts.
9
United Kingdom:
Peter Thompson is the chief executive of the Human Fertilisation and Embryology Authority (HFEA).
6
United Kingdom:
Peter Thompson, the chief executive of the HFEA, said polygenic testing was unlawful for use in the UK.
6
New Zealand:
Peter Thompson shared insights on RNZ's struggle to attract a younger audience.
5
New Zealand:
Dr Peter Thompson thinks there is a legitimate concern with kids encountering harmful content on YouTube.
7
Jamaica:
Peter Thompson, the Executive Director of the Jamaica 4-H Clubs, discussed the partnership with the Ministry of Labour to train individuals for overseas employment.
7
Jamaica:
Peter Thompson, the Executive Director of the Jamaica 4-H Clubs, discussed the partnership with the Ministry of Labour and Social Security for training individuals for an overseas employment programme.
7
Iceland:
Peter Thompson, head of the UK's Fertility and Embryology Authority, stated that only people at 'very high risk' of passing on mitochondrial diseases would be eligible for the treatment.
7
Pakistan:
Peter Thompson, head of the UK’s Human Fertilisation and Embryology Authority which approved the procedure, said only people with a 'very high risk' of passing on a mitochondrial disease would be eligible for the treatment.
7